TScan Therapeutics，一家专注于T细胞受体工程化疗法的生物技术企业，于最新提交的美国证券交易委员会（SEC）文件中正式披露，制药巨头安进（Amgen）已决定终止双方此前签署的研究合作及许可协议。这一消息源自该公司向监管机构递交的官方文件，其中明确指出了协议终结的意向。值得注意的是，安进作为全球领先的生物制药公司，此举无疑将对TScan Therapeutics的研发管线及未来战略布局产生深远影响。然而，截至发稿时，双方均未就终止合作的具体原因提供进一步详细说明。TScan Therapeutics方面表示，将仔细评估这一变化对公司在研项目及整体运营带来的潜在影响。与此同时，市场分析师也在密切关注这一动态，试图解读大型药企在细胞疗法领域合作策略的调整信号。对于TScan Therapeutics而言，此番变故或许意味着需要重新校准其研发路径，并探索新的合作机会或资金来源以继续推进其创新疗法的开发进程。后续发展，仍有待观察。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.